This comparison will cover the four classical Medhya Rasayanas — herbs classified in Charaka Samhita Chikitsa Sthana Chapter 1 as specifically promoting Medha (intelligence, memory, learning capacity) — alongside the major categories of modern pharmaceutical and nutraceutical nootropics. I will use the same evidence-evaluation framework for both: mechanism of action, human RCT evidence, effect size, safety profile, and appropriate use case.

The Medhya Rasayanas: Classical Classification

In Charaka Samhita, Chikitsa Sthana Chapter 1 (Rasayana Adhyaya, Karaprachitiya Rasayana Pada), four herbs are named explicitly as Medhya Rasayana — substances that specifically promote Medha. Each is given with a particular preparation and vehicle (anupana):

1. Mandukaparni (Centella asiatica): as swarasa (fresh expressed juice)
2. Yastimadhu (Glycyrrhiza glabra, licorice): as churna (powder) taken with milk (kshira)
3. Guduchi (Tinospora cordifolia): as swarasa (fresh juice)
4. Shankhapushpi (Convolvulus pluricaulis): as kalka (fresh whole-plant paste)

A point of frequent confusion deserves emphasis. Charaka’s first Medhya Rasayana is Mandukaparni, identified by most commentators and by the Ayurvedic Pharmacopoeia of India as Centella asiatica — not Brahmi (Bacopa monnieri). The two are listed as distinct herbs in the Pharmacopoeia, although the name “Brahmi” is applied to Bacopa across much of North India and in most modern commerce and research. Because nearly all modern clinical trials use Bacopa monnieri, I retain Bacopa in the evidence comparison below while keeping the classical identity clear. Classical tradition also regards Shankhapushpi as the foremost (shreshtha) of the medhya herbs. Ashwagandha (Withania somnifera) and Jatamansi (Nardostachys jatamansi) are not among Charaka’s named four, but are valued as rasayana and medhya herbs in the wider classical and nighantu literature and carry substantial modern evidence; I include them here for that reason rather than attributing them to a specific Medhya Rasayana verse.

Comparative Analysis: Category by Category

I group the comparison by cognitive function rather than by tradition, because that is how a real-world decision is actually made: you have a goal — consolidate memory, stay alert through a deadline, protect the aging brain — and you want the agent whose evidence best fits that goal. For each category I name the leading modern option, the closest Ayurvedic counterpart, and an honest assessment of which fits which situation.

Category 1: Memory Consolidation and Recall

Modern nootropic leader — Racetams (Piracetam, Aniracetam): The original nootropics, developed in the 1960s. Piracetam is thought to modulate AMPA-receptor function and membrane fluidity and to improve cholinergic transmission. The clinical reality is more modest than the reputation. The Cochrane systematic review of piracetam for dementia or cognitive impairment (Flicker & Grimley Evans) found an effect on clinician-rated global impression of change but no consistent benefit on specific measures of cognitive function, and concluded that the published evidence does not support routine clinical use. Evidence in healthy young adults is weaker still.

Ayurvedic equivalent — Brahmi (Bacopa monnieri): The most researched Medhya Rasayana in modern literature. A meta-analysis of nine randomized controlled trials (437 participants) of standardized Bacopa extract found a significant improvement in delayed word recall — the cognitive domain most consistently affected — together with signals on speed of attention (Trail-Making and choice reaction time). A defining feature is the time course: the pooled trials required at least 12 weeks of continuous use before effects emerged, unlike the racetams’ more acute action. The proposed mechanism — bacoside-mediated support of dendritic arborization, antioxidant activity in neural tissue, and modulation of cholinergic and BDNF pathways — is largely characterized in preclinical models, but is mechanistically distinct from the racetams, suggesting complementary rather than redundant actions.

Assessment: For sustained memory and learning support in healthy adults, Brahmi has a more convincing and better-replicated human evidence base than the racetams, with a long record of traditional use and a favourable safety profile. The trade-off is onset: weeks, not hours.

Category 2: Acute Wakefulness and Alertness

Modern nootropic leader — Modafinil: A prescription eugeroic that promotes wakefulness, primarily through dopamine-reuptake inhibition with downstream effects on histamine and orexin systems. It is well documented for sustaining alertness in shift work, jet lag, and sleep deprivation. In healthy, non-sleep-deprived subjects, a systematic review found that modafinil’s benefits are most consistent on attention, executive function, and learning, and become more apparent — not less — as task complexity increases. It carries dependency potential (lower than amphetamines), headache and anxiety risks, and is prescription-only in most countries.

Ayurvedic equivalent — Ashwagandha + Shankhapushpi combination: This pairing does not produce acute stimulant wakefulness; at equivalent single doses Ayurvedic herbs cannot match a pharmaceutical eugeroic for one-off alertness. Their strength is the opposite axis — sustained baseline function without a crash-and-anxiety cycle. Ashwagandha’s adaptogenic action lowers perceived stress and cortisol and supports sleep quality, which indirectly protects daytime cognition. In a randomized, placebo-controlled trial in adults with mild cognitive impairment, 600 mg/day of standardized root extract over eight weeks improved immediate and general memory, attention, and information-processing speed. Shankhapushpi contributes a calming, medhya effect traditionally used for anxious, scattered cognition.

Assessment: Modafinil wins for acute wakefulness in one-off situations (an overnight deadline, a critical shift). The adaptogenic combination wins for sustained baseline alertness and resilience over weeks without dependency or a withdrawal crash. These are different use cases, not direct competitors.

Category 3: Neuroprotection and Long-Term Brain Health

Modern approach — Lion’s Mane mushroom (Hericium erinaceus): A nutraceutical with growing evidence for nerve-growth-factor signalling via its hericenone and erinacine compounds. In a double-blind, placebo-controlled trial in older Japanese adults with mild cognitive impairment, Hericium erinaceus (3 g/day of dry powder, 16 weeks) improved scores on a standardized cognitive scale, with the benefit declining after the supplement was stopped. Most other supporting work for NGF/BDNF effects remains preclinical, and the human trials so far are small.

Ayurvedic equivalent — Brahmi + Ashwagandha + Jatamansi: The neuroprotective rationale for the Medhya Rasayanas is mechanistically broad, though much of it is preclinical. Bacopa shows antioxidant activity and support of dendritic growth and BDNF pathways in animal models; Withania somnifera’s withanolides (notably withanolide A) promote neurite outgrowth and dendrite formation in cultured neurons; Jatamansi’s sesquiterpenes show antioxidant and anxiolytic activity in animal studies. In humans, the strongest cognitive signals to date are Bacopa’s effect on delayed recall and Ashwagandha’s effect on memory and executive function in mild cognitive impairment, both cited above. I want to be explicit: the multi-target neuroprotective story is biologically plausible and promising, but long-term human outcome data — preventing decline over years — does not yet exist for any of these agents, Ayurvedic or nutraceutical.

Assessment: The Ayurvedic stack, particularly Brahmi + Ashwagandha, offers a mechanistically diverse and well-tolerated approach to brain aging with a reasonable short-term human evidence base. The case for long-term prevention is plausible but not yet proven by long-term trials.

Side-by-Side Comparison Table

The table below summarizes the agents discussed. “Best evidence use case” reflects where the human data are strongest, not a guarantee of benefit for any individual, and the effect-onset estimates assume standardized extracts at the research doses listed later in this article.

Dosages Used in Clinical Research

One of the most common failures in herbal nootropic research is using sub-therapeutic doses. Here are the doses that produced significant results in the trials reviewed above, alongside the traditional preparations where they differ:

• Brahmi (Bacopa monnieri): 300 mg standardized to roughly 55% bacosides daily; doses below ~200 mg tend to show minimal effect in RCTs
• Ashwagandha: 300-600 mg standardized root extract daily; 600 mg was the dose associated with improved memory and cognition in the mild-cognitive-impairment trial
• Shankhapushpi: classically given as kalka (fresh whole-plant paste); standardized extracts at 200-400 mg, or 1-2 g of churna, are the common commercial equivalents
• Jatamansi: 500 mg standardized extract, or 1-2 g churna at bedtime
• Guduchi: classically the fresh swarasa; 500 mg extract twice daily, or 3-5 g churna, in modern practice

The Stack for Different Users

Rather than “Ayurvedic vs modern nootropics,” the more productive question is: what combination serves your specific cognitive goal?

For students (exam preparation, learning new material): Brahmi 300 mg daily, with Shankhapushpi for anxious, scattered focus. Begin 10-12 weeks before the exam period to allow full onset, since the Bacopa evidence is built on roughly twelve weeks of continuous use. Add Jatamansi if exam anxiety or disturbed sleep is significant. For more on Brahmi dosage specifics based on clinical trial data, see our reference guide on Bacopa monnieri dosage from clinical trials.

For working professionals with cognitive fatigue: Ashwagandha 600 mg daily plus Brahmi 300 mg daily. The adaptogen-plus-medhya combination targets both the root (stress-mediated cognitive impairment) and the downstream symptom (impaired memory and focus).

For adults over 50 focused on long-term brain health: Brahmi 300 mg + Ashwagandha 600 mg, optionally with Lion’s Mane (Hericium erinaceus) where the nutraceutical evidence is judged worth combining. Set expectations honestly: the short-term cognitive data are reasonable, but no agent here is yet proven to prevent long-term decline.

For context on how these herbs work alongside conventional focus and concentration support, see also our guide to Ayurvedic herbs for concentration.

The Evidence Quality Question

A persistent and partly fair criticism of Ayurvedic cognitive herbs is evidence quality: many trials are small, short, single-centre, or concentrated in India, where publication bias is a genuine concern. That criticism has weakened over the past decade but has not vanished. Bacopa monnieri now has multiple randomized trials pooled in an independent meta-analysis showing a consistent effect on delayed recall, and Ashwagandha has a growing set of randomized, placebo-controlled trials on stress, sleep, and cognition from independent groups. What is still largely missing across the field is large, long-duration trials with hard outcomes, replicated outside the originating region. The honest summary is that the better Medhya Rasayana herbs have crossed from “traditional use only” into “supported by modest, repeatable human trials,” while the strongest neuroprotective claims remain mechanistically grounded but clinically unproven.

This article presents research comparisons for educational purposes and is not medical advice. Cognitive-enhancement supplements should be matched to individual health status. Modafinil and other pharmaceutical nootropics require a prescription and physician supervision. Herbal nootropics at the doses referenced have good safety profiles but should be discussed with a qualified healthcare provider or Ayurvedic practitioner, particularly if you take medications or have a health condition. Pregnant and breastfeeding women should avoid most nootropic supplements without medical guidance.

References: Charaka Samhita, Chikitsa Sthana 1 (Medhya Rasayana) | Kongkeaw et al., Bacopa monnieri meta-analysis, Journal of Ethnopharmacology 2014 | Choudhary et al., Ashwagandha and memory/cognition, Journal of Dietary Supplements 2017 | Mori et al., Hericium erinaceus and mild cognitive impairment, Phytotherapy Research 2009 | Battleday & Brem, Modafinil systematic review, European Neuropsychopharmacology 2015 | Flicker & Grimley Evans, Piracetam for dementia or cognitive impairment, Cochrane Database of Systematic Reviews.

References

1. Charaka Samhita — Rasayana Adhyaya
2. Meta-analysis of randomized controlled trials on cognitive effects of Bacopa monnieri extract (2014), PubMed
3. Efficacy and Safety of Ashwagandha (Withania somnifera (L.) Dunal) Root Extract in Improving Memory and Cognitive Functions (2017), PubMed
4. Improving effects of the mushroom Yamabushitake (Hericium erinaceus) on mild cognitive impairment: a double-blind placebo-controlled clinical trial (2009), PubMed
5. Extracellular fluid flow and chloride content modulate H(+) transport by osteoclasts (2015), PubMed
6. Cochranelibrary (cochranelibrary.com)

Nothing in this article diagnoses or treats a medical condition. Use it as educational information and consult a qualified Ayurvedic practitioner or physician before starting herbs, supplements, detoxes, or therapeutic protocols, especially if pregnant, managing a condition, or taking medication.

“Brain tonic” is too broad for a precise Ayurvedic choice. Poor retention, stress-related distractibility, disturbed sleep, mental fatigue, and progressive cognitive change are not interchangeable complaints. Brahmi and Shankhapushpi are both described as medhya in authoritative Ayurvedic sources, but their botanical identities, classical attributes, doses, and levels of modern clinical study differ substantially.

A second distinction is essential. The well-known passage in Charaka Samhita, Chikitsa Sthana 1/3/30–31, names Mandukaparni juice, Yashtimadhu powder with milk, Guduchi juice, and Shankhapushpi paste as especially intellect-promoting rasayanas. Bacopa monnieri is not one of the four drugs named in that passage. Nevertheless, the Ayurvedic Pharmacopoeia of India separately identifies Bacopa monnieri as Brahmi and assigns it the actions medhya and rasayana. Both herbs therefore have authentic Ayurvedic standing, but not through the same textual statement.

Brahmi (Bacopa monnieri): The Better-Studied Option for Memory

The Ayurvedic Pharmacopoeia of India defines Brahmi as the dried whole plant of Bacopa monnieri (Linn.) Wettst. Modern products may contain whole-plant powder or extracts standardized to selected saponins; these forms are not dose-equivalent and should not be treated as interchangeable.

Classical Ayurvedic Profile

Its recorded pharmacopoeial attributes are:

• Rasa: madhura, tikta, kashaya — sweet, bitter, and astringent
• Guna: laghu and sara — light and mobile or flowing
• Virya: shita — cooling
• Vipaka: madhura — sweet post-digestive effect
• Karma: includes medhya, rasayana, matiprada, Vatahara, and Kaphahara

The pharmacopoeia lists Sarasvatarishta, Brahmi Ghrita, Brahmi Vati, Sarasvata Churna, and Smritisagara Rasa among important formulations associated with Brahmi. Raw herb, extract capsules, and compound formulations remain therapeutically distinct.

Human Clinical Evidence

Bacopa has a larger human evidence base than Convolvulus pluricaulis. A 2001 randomized, double-blind, placebo-controlled trial of a standardized extract reported improvements after 12 weeks in visual information-processing speed, learning rate, memory consolidation, and state anxiety. A separate 2002 trial in adults aged 40–65 found a significant effect on retention of newly learned word pairs, with the pattern suggesting reduced forgetting rather than a broad improvement across every memory measure.

A 2012 systematic review found the most consistent signal in memory free recall, while effects in other cognitive domains were less consistent. A 2014 meta-analysis of randomized controlled trials concluded that Bacopa had potential cognitive benefits, particularly for speed of attention, while also calling for larger and better-designed trials. Standardized Bacopa extracts may improve selected outcomes in some adults after repeated use, but they are not established dementia treatments or universal remedies for poor concentration.

More recent evidence also argues against certainty. A 12-week randomized trial published in 2025 found no greater improvement in cognitive performance than placebo, although it reported signals for reduced stress and fatigue. Differences among extracts and study designs make product-specific interpretation important.

What Is Known About Mechanism

Bacopa contains dammarane-type triterpenoid saponins commonly grouped under the term bacosides. Laboratory and animal studies have examined antioxidant activity, cholinergic signaling, monoamine systems, synaptic plasticity, and neuroprotective pathways. Some human studies have also measured acetylcholinesterase-related outcomes. These findings do not justify equating Bacopa with donepezil or reducing its effects to one neurotransmitter pathway.

Shankhapushpi (Convolvulus pluricaulis): Classical Medhya Rasayana with Limited Human Data

The Ayurvedic Pharmacopoeia of India defines Shankhapushpi as the whole plant of Convolvulus pluricaulis Choisy. It also notes that Clitoria ternatea and Evolvulus alsinoides are used as Shankhapushpi in some parts of India. A label carrying the common name “Shankhpushpi” may therefore contain a different species from the one used in a study or monograph.

Classical Ayurvedic Profile

For pharmacopoeial Convolvulus pluricaulis, the recorded Ayurvedic attributes are:

• Rasa: tikta, kashaya — bitter and astringent
• Guna: sara — mobile or flowing
• Virya: shita — cooling
• Vipaka: madhura — sweet post-digestive effect
• Karma: includes medhya, rasayana, balya, ayushya, Kaphahara, Pittahara, and mohanashaka

Charaka’s medhya-rasayana passage specifies Shankhapushpi in paste form. The pharmacopoeia lists Brahmi Ghrita, Agastyaharitaki Rasayana, Brahma Rasayana, Manasamitra Vataka, Gorocanadi Vati, and Brahmi Vati among important formulations associated with Shankhapushpi. A formulation name containing “Brahmi” does not establish that every modern product contains both herbs.

Experimental Evidence and Its Limits

Animal studies have reported memory-related, anxiolytic, and central nervous system depressant effects from Convolvulus pluricaulis extracts. A 2011 study evaluated several extracts in rodents and found activity in learning, memory, anxiety, and locomotor models, with results varying by extract and dose. Phytochemical investigations describe alkaloids, coumarins, flavonoids, and sterols, with profiles varying by material and extraction method.

Human clinical evidence for authenticated Convolvulus pluricaulis remains sparse. It is therefore inaccurate to assign it a proven four-to-six-week onset, a validated GABA mechanism in patients, or superiority over Bacopa for anxiety. Its contemporary use is best framed as a classical Ayurvedic choice requiring individualized prescribing, not a standardized nootropic protocol.

Head-to-Head Comparison

No robust direct human trial establishes that one of these herbs is categorically superior to the other. A useful comparison separates classical pharmacopoeial information from modern clinical evidence.

Clinical Decision Framework

Ayurvedic selection should consider the person, the complaint, digestive tolerance, concurrent medicines, and the exact preparation. Constitution alone is insufficient, and neither herb should be chosen solely from an online dosha quiz.

When Brahmi May Be the More Defensible Starting Point

Brahmi is the more evidence-supported option when the goal is a time-limited trial for memory retention or selected attention outcomes in an otherwise medically assessed adult. Considerations include:

• Difficulty retaining newly learned information without sudden or progressive neurological symptoms
• A preference for a product standardized in the same way as a published human trial
• Willingness to use it consistently for the trial period rather than expecting an immediate stimulant effect
• Access to professional review of gastrointestinal tolerance, thyroid status, and possible medicine interactions

When Shankhapushpi May Be Considered

Shankhapushpi may be selected within an Ayurvedic plan when its classical medhya, rasayana, Pittahara, and Kaphahara profile fits the assessed presentation. Practical requirements are:

• Confirmation that the product contains Convolvulus pluricaulis rather than an unspecified substitute
• Use of the whole herb or a clearly characterized preparation rather than assuming all syrups are equivalent
• Practitioner supervision when the complaint includes anxiety, insomnia, seizures, thyroid disease, or regular medication use
• Realistic expectations, because a clinically validated onset time and comparative superiority have not been established

Should They Be Combined?

A combination is not automatically more effective. Classical and proprietary formulations may contain multiple medhya herbs, but their rationale, proportions, processing, and adjuvants are formulation-specific. A fixed schedule of 300 mg Bacopa extract plus 3 g Shankhapushpi is neither a universal classical protocol nor a validated combined regimen. Combination use should follow a qualified practitioner’s assessment.

Dosing and Dosage Forms

Dose must be tied to the exact material. A gram dose of whole-plant powder cannot be converted directly into a milligram dose of concentrated extract, and commercial syrups may also contain several ingredients.

Brahmi

The Ayurvedic Pharmacopoeia of India gives 1–3 g of the drug in powder form. Several adult cognition trials used about 300 mg daily of a particular standardized extract, but the extract specification is part of the dose and cannot be omitted. Brahmi Ghrita is an official classical formulation associated with the herb; its dose should follow the applicable formulary, product directions, and practitioner advice rather than being inferred from raw-herb dosing.

Shankhapushpi

The pharmacopoeial dose is 3–8 g of the drug in powder form. It does not establish a universal dose for juice, syrup, tablets, or concentrated extracts. Because several species circulate under the common name, check the botanical name and plant part.

Ghee, Milk, and Black Pepper

Ghee has an established place in Ayurvedic dietetics and in classical medicated-ghee formulations used for medhya purposes. That use does not prove that ghee increases absorption of every constituent in either herb. Likewise, adding black pepper is not automatically appropriate; piperine can alter drug metabolism, and no universal Brahmi–Shankhapushpi protocol requires it.

Safety Considerations and Interactions

“Natural” does not mean interaction-free. Product authentication, dose, duration, age, pregnancy status, medical conditions, and concurrent medicines all affect safety.

• Brahmi: Human trials most often report gastrointestinal effects such as increased stool frequency, abdominal cramps, and nausea. Caution is appropriate with thyroid disease or thyroid hormone, cholinergic or anticholinergic medicines, and drugs affected by CYP enzymes.
• Shankhapushpi: Human safety and interaction data for authenticated Convolvulus pluricaulis are limited. Do not use animal thyroid findings to alter levothyroxine, antithyroid medicine, or endocrine care.
• Pregnancy and breastfeeding: Avoid self-prescribing either herb because adequate human safety data and product consistency are lacking.
• Children and older adults: Dosing should be individualized by a qualified Ayurvedic practitioner or healthcare professional, especially when other medicines are used.
• Persistent symptoms: New, worsening, or progressive memory change, confusion, severe anxiety, sleep disruption, or functional decline requires medical evaluation rather than treatment with a nootropic supplement alone.

Consult a qualified Ayurvedic practitioner and the relevant healthcare provider before starting either herb, particularly if you are pregnant, breastfeeding, treating a thyroid or neurological condition, or taking prescription medication.

Bottom Line

Brahmi and Shankhapushpi are not interchangeable “brain herbs.” Bacopa monnieri has the stronger human research base for selected memory and attention outcomes, although results are mixed and extract-specific. Convolvulus pluricaulis has a particularly clear classical position as one of Charaka’s medhya rasayanas, but its modern human evidence is much thinner and botanical substitution is a major practical concern. The sound choice depends on authenticated material, the precise clinical goal, the Ayurvedic assessment, and safety review—not on claims of a universal best nootropic.

References

1. Ayurvedic Pharmacopoeia of India
2. Ayurvedic Pharmacopoeia of India
3. Charaka Samhita — Buddhi
4. The chronic effects of an extract of Bacopa monniera (Brahmi) on cognitive function in healthy human subjects (2001), PubMed
5. Chronic effects of Brahmi (Bacopa monnieri) on human memory (2002), PubMed
6. The cognitive-enhancing effects of Bacopa monnieri: a systematic review of randomized, controlled human clinical trials (2012), PubMed
7. Meta-analysis of randomized controlled trials on cognitive effects of Bacopa monnieri extract (2014), PubMed
8. The Effects of a Bacopa monnieri Extract (Bacumen(®)) on Cognition, Stress, and Fatigue in Healthy Adults: A Randomized, Double-Blind, Placebo-Controlled Trial (2025), PubMed
9. Neuropharmacological review of the nootropic herb Bacopa monnieri (2013), PubMed Central
10. Effects of 12-Week Bacopa monnieri Consumption on Attention, Cognitive Processing, Working Memory, and Functions of Both Cholinergic and Monoaminergic Systems in Healthy Elderly Volunteers (2012), PubMed
11. Nootropic, anxiolytic and CNS-depressant studies on different plant sources of shankhpushpi (2011), PubMed
12. Phytochemical Profile, Pharmacological Attributes and Medicinal Properties of Convolvulus prostratus – A Cognitive Enhancer Herb for the Management of Neurodegenerative Etiologies (2020), PubMed Central
13. Does Bacopa monnieri improve memory performance in older persons? Results of a randomized, placebo-controlled, double-blind trial (2010), PubMed
14. NCBI
15. Piperine, a major constituent of black pepper, inhibits human P-glycoprotein and CYP3A4 (2002), PubMed
16. Predicting Food-Drug Interactions between Piperine and CYP3A4 Substrate Drugs Using PBPK Modeling (2024), PubMed